Adams Capital Management Portfolio Companies

Precision Therapeutics

Initial Investment:

2003

Location:

Pittsburgh, Pennsylvania

ACM Deal Team:

Joel Adams (Director)
William Frezza

Overview:

Precision Therapeutics (PTI) is committed to improving outcomes of cancer patients. Known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, PTI develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer. PTI's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician with the goal of optimizing patient outcomes.
www.precisiontherapeutics.com

Recent Precision Therapeutics News

May 9, 2013	Precision Therapeutics Presents Clinical Data Demonstrating Prediction for Platinum Resistance to First-Line Chemotherapy in Primary Ovarian Cancer at WAGO
May 6, 2013	Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to Be Presented by Precision Therapeutics at WAGO Annual Meeting

Current Portfolio

Information Technology:

Networking Infrastructure